EGF and metastatic colorectal cancer: Anti-EGFR and anti-VEGF antibodies are already used to a large extent to treat metastatic colorectal cancer [44], therefore overexpression of genes from the EGF and VEGF pathways in sporadic EOCRC could improve the response rates to these targeted therapies.